Polen Thomas E Jr reported option exercise involving 20,239 derivative units of BECTON DICKINSON CO at $0.00 for $0 on Nov 5, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chairman, CEO and President
Chairman, CEO and President
Filed Nov 9, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
20,239Stock Appreciation Rights
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
20,239Direct
Trade date
Nov 5, 2026Option exercise
Filed
Nov 9, 2026, 5:44 PM ET4-day reporting delay
Accession
0001628280-26-072360Code M · Transaction 396353
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 5, 2026Sell2,993$210.00−$628,530Trade 396352
Nov 5, 2026Option exercise20,239$178.94$3,621,566.66Trade 396350
Nov 5, 2026Disposition to issuer17,246$210.00−$3,621,660Trade 396351
4 transaction rows in this filing. Joint filers share the same rows.

BDX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BDX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −16%1w ago −7.9%1d ago −2.8%
Returns since7d30d90d180d1y

Footnotes in full

F1: Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2: The stock appreciation rights vest in four annual installments beginning November 26, 2019.